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Introduction: This study investigated the incidence of delayed norepinephrine administration following the onset
of septic shock and its effect on hospital mortality.
Methods: We conducted a retrospective cohort study using data from 213 adult septic shock patients treated at
two general surgical intensive care units of a tertiary care hospital over a two year period. The primary outcome
was 28-day mortality.
Results: The 28-day mortality was 37.6% overall. Among the 213 patients, a strong relationship between delayed
initial norepinephrine administration and 28-day mortality was noted. The average time to initial norepinephrine
administration was 3.1 ± 2.5 hours. Every 1-hour delay in norepinephrine initiation during the first 6 hours after
septic shock onset was associated with a 5.3% increase in mortality. Twenty-eight day mortality rates were significantly
higher when norepinephrine administration was started more than or equal to 2 hours after septic shock onset (Late-NE)
compared to less than 2 hours (Early-NE). Mean arterial pressures at 1, 2, 4, and 6 hours after septic shock onset were
significantly higher and serum lactate levels at 2, 4, 6, and 8 hours were significantly lower in the Early-NE than the
Late-NE group. The duration of hypotension and norepinephrine administration was significantly shorter and the
quantity of norepinephrine administered in a 24-hour period was significantly less for the Early-NE group compared to
the Late-NE group. The time to initial antimicrobial treatment was not significantly different between the Early-NE and
Late-NE groups.
Conclusion: Our results show that early administration of norepinephrine in septic shock patients is associated with an
increased survival rate.Introduction
Septic shock is the most challenging problem in critical
care medicine and has a very high mortality [1-3]. Owing
to the complex pathophysiology, the outcomes for septic
shock patients remain disappointing. Rivers et al.
demonstrated that early goal-directed therapy provided
significant benefits with respect to outcomes for septic
shock patients [4]. However, massive fluid resuscitation
may increase extravascular edema, aggravate pulmonary
dysfunction and compromise tissue oxygenation [5,6].
Therefore, investigating the rational use of vasopressors in
septic shock is very important. Thus far, most studies
have focused on the rational use of different types of
vasopressors [7-9], and the third edition of the guidelines* Correspondence: yudrnj@163.com; baixiaowudoctor@foxmail.com
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unless otherwise stated.for management of severe sepsis and septic shock also
concentrates on the choice of vasopressors [10]. However,
it is the timing of vasopressor therapy, rather than the
specific agent, that appears to be crucial [11]. The current
guidelines recommend that vasopressors (norepinephrine
as the first choice) be administered for hypotension
refractory to initial fluid resuscitation and to maintain a
mean arterial pressure (MAP) ≥65 mm Hg, and this should
be completed within six hours [10]. According to the
guidelines, physicians currently prefer fluid resuscitation
without vasopressors until a lack of hypotension correction
is confirmed. However, this may result in prolonged
hypotension, and valuable time may have passed. For
example, some vital organs could be damaged irreversibly
because of low perfusion. In addition, some researchers
have argued that early initiation of norepinephrine
administration, especially when hypovolemia has not been
resolved, can adversely affect vital organ microcirculatoryThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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study examined the relationship between delay in initial
norepinephrine administration and hospital mortality
and investigated the effects of early norepinephrine
administration on septic shock.
Material and methods
This retrospective cohort study was conducted in two
general surgical intensive care units (ICUs) of a tertiary
care hospital, Jinling Hospital in Nanjing, China, which
mainly admit patients with severe complications after
surgery and severe trauma. In these ICUs, vasopressors
were administered according to the Surviving Sepsis
Campaign (SSC) guidelines [14]. First, initial fluids
resuscitation termed early goal-directed therapy and early
antimicrobial treatment were administered as soon as
sepsis-induced tissue hypoperfusion was recognized [4].
Then, when the physicians judged that hypotension did
not respond to initial fluids resuscitation, vasopressor
therapy was initiated with the aim of maintaining MAP at
least 65 mm Hg and norepinephrine was the first-choice
vasopressor.
The study was approved by the Institutional Review
Board of Jinling Hospital. Because all data were anonymous
and collected retrospectively, the Institutional Review
Board of Jinling Hospital waived the need for informed
consent.
Study patients
We reviewed the medical records of all adult (≥18 years of
age) patients with a diagnosis of septic shock as described
by the SCCM/ESICM/ACCP/ATS/SIS International
Sepsis Definitions Conference [15]. Sepsis was definedFigure 1 Inclusion and exclusion flowchart.as the presence of infection (documented or probable)
with systemic manifestations of infection [15]. Septic shock
was defined as sepsis-induced, persisting hypotension,
which was defined as systolic blood pressure <90 mm Hg,
a decrease of 40 mm Hg in systolic pressure from the
patient’s baseline or MAP <65 mm Hg. An episode of
hypotension was deemed to represent septic shock when
(1) hypotension persisted from the onset despite adequate
fluid resuscitation (30 mL/kg crystalloid fluids) or (2)
hypotension was only transiently improved (for <1 hour)
with adequate fluid resuscitation. All included patients
were treated from January 2011 to December 2012 and
had no other obvious cause of shock. The inclusion
flowchart is described in Figure 1.
Data collection
The collected data included age, gender, body weight,
serum lactate, MAP, the Acute Physiology and Chronic
Health Evaluation (APACHE) II scores based on the worst
values obtained within 24 hours after the onset of septic
shock, documented infections, microbiologic results,
primary infection site, volume (L) of intravenous fluids
administered within 6 and 24 hours after the onset of
septic shock (including crystalloid, colloid and blood
products), quantity (mg) of norepinephrine administration
within the 24 hours after the onset of septic shock, time
(hours) to initial norepinephrine administration, time
(hours) to initial antimicrobial treatment, effective anti-
microbial therapy, corticosteroid treatment, norepinephrine
duration, hypotension duration, ICU duration and 28-day
mortality. Two investigators independently reviewed the
included records using a standardized data collection form.
A third author resolved any discrepancies.









Age (years) 58.2 ± 11.9 59.5 ± 14.4 0.507
Gender, number (%) 0.684
Male 71 (53.4) 45 (56.2)
Female 62 (46.6) 35 (43.8)
Weight (kg) 64.0 ± 13.8 64.7 ± 13.2 0.708
Serum lactate at septic shock
onset (mmol/L)
4.3 ± 1.4 5.3 ± 1.5 <0.001
APACHE II score 27.2 ± 3.9 30.4 ± 3.9 <0.001
Documented infection,
number (%)
117 (88.0) 74 (92.5) 0.293
Culture positive, number (%) 108 (81.2) 67 (83.8) 0.638
Primary infection site, number (%) 0.675
Respiratory 23 (17.3) 18 (22.5)
Intra-abdominal 46 (34.6) 28 (35.0)
Genitourinary 13 (9.8) 5 (6.3)
Skin and soft tissue 5 (3.8) 2 (2.5)
Intravascular catheter 15 (11.3) 10 (12.5)
Bloodstream 8 (6.0) 8 (10.0)
Other 23 (17.3) 9 (11.3)
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We calculated an APACHE II score to assess the severity
of illness. Time to initial administration of norepinephrine
was calculated from the onset of septic shock to initial
norepinephrine administration. Effective antimicrobial
therapy was declared when the first administration of a
new antimicrobial to which the pathogen was susceptible
or that matched national guidelines in cases of culture-
negative septic shock was initiated within six hours after
the onset of septic shock. Time to initial antimicrobial
treatment was calculated from the onset of septic shock.
Corticosteroid treatment was defined to have occurred if
it was started within six hours after the onset of septic
shock. Documented infection was concluded when a
plausible pathogen from the blood or infection site
was identified with a compatible syndrome or when
infection was supported by a definitive surgical, radiologic
or pathologic diagnosis. All other infections were declared
to be suspected. The primary infection site was ascertained
by the consensus of three researchers. ICU duration was
calculated from the time of patient admission instead of the
onset of septic shock.
Statistical analysis
We compared the Early-NE group to the Late-NE group
(which received norepinephrine <2 hours and ≥2 hours
after the onset of septic shock, respectively) based on
the odds ratio (OR) analysis. Data were analyzed with
SPSS software, version 19.0 (SPSS, Inc., Chicago, IL,
USA). Values were expressed as the means ± standard
deviation (SD) (continuous variables) or as a percentage
of the group from which they were derived (categorical
variables). Continuous variables were compared using
the Student t-test for normally distributed variables and
the Mann–Whitney U test for non-normally distributed
variables. Categorical variables were compared using the
chi-square or Fisher’s exact test. All comparisons were
unpaired, and all P values were two-tailed. A P value ≤0.05
was considered to indicate statistical significance.
Logistic regression analysis was performed to examine
28-day mortality as a function of time to initial norepineph-
rine administration. The primary outcome variable was
28-day mortality, and the primary independent variable
was time to initial norepinephrine administration as a
continuous variable. In addition, multivariate logistic
regression was undertaken to examine the independent
effect of variables on 28-day mortality, and the results are
reported as adjusted ORs of death with their corresponding
95% confidence intervals (CI).
Results
These analyses included 213 patients. All patients received
norepinephrine as the initial vasopressor agent. The
overall 28-day mortality was 37.6%.Initial serum lactate level was 4.7 ± 1.5 mmol/L and
the APACHE II score was 28.4 ± 4.2. Infections were
documented in 191 cases (89.7%); the remaining cases
represented suspected infections without a positive
culture or definitive surgical, radiologic, biopsy, or autopsy
evidence of infection. Positive cultures were identified in
175 cases (82.2%). A plausible microbial pathogen was
isolated from the blood in 132 cases (62.0%).
There were no significant differences between survivors
and non-survivors with respect to age, gender or the
frequencies of documented infections and positive
cultures or source of infection. Initial serum lactate
levels and APACHE II scores were significantly higher
in the non-survivors than in the survivors (Table 1).
Survivors received more intravenous fluids within
6 hours (3.4 ± 0.9 L versus 3.0 ± 0.9 L; P =0.003) but
less intravenous fluids within 24 hours (6.5 ± 0.8 L
versus 6.9 ± 0.5 L; P <0.001) than the non-survivors.
They also received less norepinephrine within 24 hours
(29.4 ± 9.7 mg versus 34.8 ± 9.6 mg; P <0.001). Survivors
also had a shorter time to initial norepinephrine adminis-
tration (2.7 ± 2.1 hours versus 3.8 ± 2.9 hours; P =0.002),
had a shorter time to initial antimicrobial treatment
(1.4 ± 1.2 hours versus 2.2 ± 1.8 hours; P =0.001) and
received effective antimicrobial therapy more frequently
(72.9% versus 56.3%; P =0.012) (Table 2). The survivors
were treated with norepinephrine for a shorter duration
Table 2 Therapeutic intervention and secondary outcomes: Phase I
Characteristic 28-day survivors (n = 133) 28-day non-survivors (n = 80) P value
24-hour norepinephrine administration (mg) 29.4 ± 9.7 34.8 ± 9.6 <0.001
Time to initial norepinephrine administration (h) 2.7 ± 2.1 3.8 ± 2.9 0.002
Time to initial antimicrobial treatment (h) 1.4 ± 1.2 2.2 ± 1.8 0.001
Volume of intravenous fluids within 6 h (L) 3.4 ± 0.9 3.0 ± 0.9 0.003
Volume of intravenous fluids within 24 h (L) 6.5 ± 0.8 6.9 ± 0.5 <0.001
Effective antimicrobial therapy, number (%) 97 (72.9) 45 (56.3) 0.012
Corticosteroid treatment, number (%) 78 (58.6) 50 (62.5) 0.578
Norepinephrine duration (days) 2.4 ± 0.6 3.4 ± 0.9 <0.001
ICU duration (days) 11.2 ± 5.7 10.8 ± 5.4 0.646
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The frequency of corticosteroid treatment was similar
in the survivors and the non-survivors. Overall, the
average time to initial norepinephrine administration
was 3.1 ± 2.5 hours. A total of 18.8% of all patients
received norepinephrine administration within 1 hour
after the onset of septic shock, 40.4% within 2 hours
and 9.9% of patients ≥6 hours after the first occurrence of
septic shock (Figure 2). The relationship between hospital
mortality and the time to initial norepinephrine adminis-
tration is shown in Figure 3. Mortality was 27.5% if
norepinephrine administration was initiated <1 hour after
the onset of septic shock, 30.4% if initiated from 1 to
2 hours after the onset and 65.2% if initiated ≥6 hours
after the onset. Twenty-eight-day mortality was sig-
nificantly higher in patients who received norepineph-
rine ≥2 hours after septic shock onset and increased
when compared to those who received it <2 hours after
onset (OR for death =1.86; 1.04 to 3.34; P =0.035;
Figure 4). The OR of death was 2.16 (1.23 to 3.81, P =0.007)Figure 2 Cumulative norepinephrine initiation. Bars represent
the fraction of patients who received initial norepinephrine
administration from the time of septic shock onset to the indicated
ending time point.when norepinephrine was administered after three
hours and 3.61 (1.45 to 8.95, P =0.004) when given after
six hours (Figure 4).
In univariate logistic regression analysis, the time from
the onset of septic shock to initial norepinephrine
administration was an important determinant of 28-day
mortality. The OR of death was 1.20 per hour delay
(1.07 to 1.35, P =0.002), that is, every 1-hour delay was
associated with a 20.4% increased probability of death.
The 28-day mortality was 29.1% in the Early-NE group
(within two hours) and 43.3% in the Late-NE group
(after two hours). There were no significant differences
with respect to age, gender, weight, APACHE II score,
documented infections, positive cultures and primary
infection sites between the Early-NE and the Late-NE
group (Table 3). Serum lactate levels at the onset of
septic shock were even significantly higher in the Early-NE
group than in the Late-NE group (Table 3).
Patients in the Early-NE group received less intravenous
fluid within 24 hours (6.2 ± 0.6 L versus 6.9 ± 0.7 L;
P <0.001) and less norepinephrine within 24 hours
(29.4 ± 9.7 mg versus 32.8 ± 10.0 mg; P =0.013) (Table 4).Figure 3 Mortality of patients whose initial norepinephrine
administrations were within the indicated time interval.
Figure 4 Relationship between different norepinephrine
administration delays and hospital mortality expressed as odds
ratio of death. Bars represent 95% confidence interval. The y-axis
represents different norepinephrine administration time delays from
the onset of septic shock.
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in the onset of intravenous fluid therapy, the time to
initial antimicrobial treatment, the frequency of effective
antimicrobial therapy and the frequency of corticosteroid
treatment (Table 4). The duration of hypotension was
shorter in the Early-NE group (4.6 ± 1.2 hours versus
6.1 ± 1.0 hours; P <0.001), and the duration of norepin-
ephrine was also statistically shorter in these patients
(2.6 ± 0.6 days versus 2.9 ± 1.0 days; P =0.001). There
was no significant difference in the duration of ICUTable 3 Demographic data and baseline characteristics: Phase
Characteristic <2 hours (numb




Weight (kg) 64.7 ± 14.4
Serum lactate at septic shock onset (mmol/L) 5.0 ± 1.7
APACHE II score 28.6 ± 4.6
Documented infection, number (%) 77 (89.5)
Culture positive, number (%) 73 (84.9)




Skin and soft tissue 3 (3.8)
Intravascular catheter 10 (11.3)
Bloodstream 7 (6.0)
Other 10 (17.3)stay. Mean arterial pressure was higher at one, two,
four and six hours after the onset of septic shock and
serum lactate levels at two, four, six and eight hours
after the onset of septic shock were significantly lower
in the Early-NE group than in the Late-NE group (P <0.05,
Figure 5). Multivariate logistic regression analysis identified
the time to initial norepinephrine administration, the time
to initial antimicrobial treatment, serum lactate level at the
onset of septic shock, APACHE II score, intravenous fluid
therapy within six hours and effective antimicrobial therapy
as independent determinants of 28-day mortality (Table 5).
Discussion
The present data show that the time from the onset of
septic shock to initial norepinephrine administration is
an important determinant of survival. The risk of death was
significantly increased with longer delay in norepinephrine
initiation after the onset of septic shock. For every one-
hour delay in norepinephrine initiation within six hours
after the onset of septic shock, the mortality increased by
5.3%. This could not be attributed to the more severe septic
shock in the delayed norepinephrine initiation group. Initial
blood pressure levels were similar. On the contrary,
patients in the Early-NE group had higher serum lactate
levels than those in the Late-NE group.
Early norepinephrine administration reduced the
duration and the total dose of norepinephrine treatment
and shortened the duration of shock with less intravenous
fluid requirements (a 10% decrease in the first 24 hours
for treatment). These data suggest that in the case of
severe septic shock, early norepinephrine administrationII
er = 86) ≥2 hours (number = 127) P value




64.0 ± 12.9 0.731
4.4 ± 1.4 0.011











Table 4 Therapeutic intervention and secondary outcomes: Phase II
Characteristic <2 hours (number = 86) ≥2 hours (number = 127) P value
24-hour norepinephrine administration (mg) 29.4 ± 9.7 32.8 ± 10.0 0.013
Time to initial antimicrobial treatment (h) 1.6 ± 1.4 1.7 ± 1.5 0.126
Volume of intravenous fluids within 6 h (L) 3.1 ± 0.9 3.3 ± 0.8 0.092
Volume of intravenous fluids within 24 h (L) 6.2 ± 0.6 6.9 ± 0.7 <0.001
Effective antimicrobial therapy, number (%) 55 (64.0) 87 (68.5) 0.489
Corticosteroid treatment, number (%) 54 (62.8) 74 (58.3) 0.508
Norepinephrine duration (days) 2.6 ± 0.6 2.9 ± 1.0 0.001
Hypotension duration (h) 4.6 ± 1.2 6.1 ± 1.0 <0.001
ICU duration (days) 10.7 ± 6.0 11.2 ± 5.2 0.520
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[10,14], fluids and antimicrobials should be administered
as early as possible in patients with septic shock, but the
optimal timing of vasopressor administration is less clear.
The patients with septic shock receiving vasopressors
early or late depend on the patient’s response to initial
fluid resuscitation and the judgment of the physicians. It
remains difficult to determine if late administration ofFigure 5 Changes of MAP and serum lactate level following the
onset of septic shock in the Early-NE group and the Late-NE
group. Bars represent standard deviation. *P <0.05 for the
comparison of the Early-NE group to the Late-NE group. MAP, mean
arterial pressure; NE, norepinephrine.norepinephrine reflects a poor evaluation of the disease
severity of the patient and if the higher mortality is related
to a globally less appropriate management of the patients.
Our results also indicate that although the time to initial
antimicrobial treatment was not significantly different
between the Early-NE group and the Late-NE group, it
was significantly longer in the non-survivor group than
the survivor group and it is a critical determinant of
outcome. In the multivariate logistic regression analyses,
time to initial antimicrobial treatment was a significant
independent risk factor for 28-day mortality, a result
consistent with prior observations [16,17]. Kumar et al.
reported a linear increase in the risk of mortality for each
hour delay in antibiotic therapy [16]. The percentage of
patients with positive blood cultures was 62% in our study
compared to around 40% in other studies [16]. Some
factors may have influenced these results. First, our ICUs
were general surgical ICUs and most patients admitted to
them had severe intra-abdominal infections or intestinal
fistulae, whereas most of the other studies were conducted
in medical ICUs and mixed ICUs. The bias between the
different patient characteristics might be one reason for
the different results. Second, most patients in our study
underwent multiple surgical interventions, including
surgical puncture, which would increase the opportunity
for pathogens to enter the blood. Other factors could have
influenced the results of positive blood cultures as well
(for example, nosocomial infection).
Additionally, our data show that the time to initial nor-
epinephrine administration, the time to initial antimicrobial
treatment, serum lactate level at the onset of septic shock,
APACHE II score, intravenous fluids within six hours
and effective antimicrobial therapy were independently
associated with hospital mortality.
The results of this study are consistent with those re-
ported in some previous studies [18,19]. In a retrospective
study, Morimatsu et al. reported that survival of septic
shock patients treated with early and exclusive norepin-
ephrine administration (median time 1.3 hours) compared
favorably with that predicted by severity scores [19]. In
Table 5 Multivariate logistic regression analysis of independent risk factors for 28-day mortality
Variable Adjusted Odds Ratio of Death 95% Confidence interval P value
Risk factors
Time to initial norepinephrine administration (h) 1.392 1.138–1.702 0.003
Time to initial antimicrobial treatment (h) 1.330 1.067–1.659 0.011
Serum lactate at septic shock onset (mmol/L) 1.710 1.174–2.537 0.005
APACHE II score 1.243 1.096–1.409 <0.001
Protective factors
Effective antimicrobial therapy 0.477 0.231–0.982 0.040
Volume of intravenous fluids within 6 h (L) 0.676 0.468–0.977 0.033
Hosmer-Lemeshow goodness-of-fit test, P =0.627.
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effects of early versus delayed norepinephrine administra-
tion, and showed that the mesenteric/aortic blood flow
ratio was higher and blood lactate concentrations lower in
an early compared to a late norepinephrine group [18].
Additionally, early norepinephrine administration spared
approximately 30% of the fluid volume required in
the late or non-norepinephrine groups [18]. In another
retrospective study, Subramanian et al. found that liberal
vasopressor use was not associated with less progression
to organ failure in septic shock [20]. However, the volume
of fluids received within six hours was significantly greater
in the liberal than in the conservative group and they
used different types of vasopressors, including dopamine,
phenylephrine, norepinephrine and vasopressin. Their
study was also conducted in a medical ICU, so that differ-
ences in patient characteristics may have influenced the
results as well.
Septic shock is characterized by hypotension, related
in part to absolute and relative hypovolemia. The former
is the result of vascular leakage caused by endothelial
injury and the latter is the result of systemic vasodilation
[21]. In addition, sepsis can result in down-regulation of
norepinephrine receptors [22]. Increased MAP with
norepinephrine may improve organ perfusion and this
may result in lower serum lactate levels. Therefore,
expedited norepinephrine administration can be a rational
approach to rapidly restore organ perfusion. One may,
therefore, be recommended to initiate norepinephrine
administration simultaneously with fluid resuscitation at
the onset of septic shock. Obviously, this strategy should
not prevent adequate fluid resuscitation, as one must
pay attention to a so-called ‘vasoconstrictor-masked
hypovolemia’ [23].
Our study has several important limitations. First, the
retrospective trial design limits our ability to identify
precisely the causes for delay in initial vasopressor
administration and to determine a causal relationship
between the delay in norepinephrine administration and
the septic-shock mortality. In addition, the sample sizewas relatively small. Therefore, large multicenter pro-
spective cohort studies are needed to validate whether
early norepinephrine administration is associated with
decreased mortality in patients with septic shock.
Conclusions
This study indicates that early administration of nor-
epinephrine for septic shock is associated with improved
survival. Mortality increases when initial norepinephrine
administration is delayed. Early norepinephrine initiation
can increase MAP, shorten the duration of hypotension
and, thereby, may improve vital organ perfusion and
decrease serum lactate levels. These data suggest that more
prompt and aggressive norepinephrine administration
should be considered as part of initial resuscitation therapy
for septic shock.
Key messages
 Early administration of norepinephrine increases the
survival rate of septic shock patients.
 Early norepinephrine initiation can increase MAP,
shorten the duration of hypotension and, thereby,
may improve vital organ perfusion and decrease
serum lactate levels.
 The time to initial norepinephrine administration,
the time to initial antimicrobial treatment, serum
lactate level at the onset of septic shock, APACHE II
score, intravenous fluid therapy within six hours and
effective antimicrobial therapy are independently
associated with hospital mortality.
 More prompt and aggressive norepinephrine
administration should be considered as part of initial
resuscitation for septic shock.
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